Page 50 - Read Online

Page 16 of 16 Tu et al. J Cancer Metastasis Treat 2018;4:58 I http://dx.doi.org/10.20517/2394-4722.2018.67

43. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histo-
logic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
44. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell
2003;3:537-49.
45. Hugo HJ, Gunasinghe N, Hollier BG, Tanaka T, Blick T, et al. Epithelial requirement for in vitro proliferation and xenograft growth and
metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin. Breast Cancer Res
2017;19:86.
46. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometas-
tases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:3678-85.
47. Jerby L, Wolf L, Denkert C, Stein GY, Hilvo M, et al. Metabolic associations of reduced proliferation and oxidative stress in advanced
breast cancer. Cancer Res 2012;72:5712-20.
48. Giese A, Loo MA, Tran N, Haskett D, Coons SW, et al. Dichotomy of astrocytoma migration and proliferation. Int J Cancer 1996;67:275-
82.
49. Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A. ‘Go or grow’: the key to the emergence of invasion in tumour progression?
Math Med Biol 2012;29:49-65.
50. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, et al. Biological and molecular heterogeneity of breast cancers correlates with
their cancer stem cell content. Cell 2010;140:62-73.
51. Dembinski JL, Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarci-
noma. Clin Exp Metastasis 2009;26:611-23.
52. Liu S, Cong Y, Wang D, Sun Y, Deng L, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of
their normal counterparts. Stem Cell Reports 2014;2:78-91.
53. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014;14:275-91.
54. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 2017;14:611-
29.
55. Beca F, Polyak K. Intratumor Heterogeneity in Breast Cancer. Adv Exp Med Biol 2016;882:169-89.
56. Pinheiro C, Garcia EA, Morais-Santos F, Moreira MA, Almeida FM, et al. Reprogramming energy metabolism and inducing angiogenesis:
co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas. BMC Cancer 2015;15:835.
57. Scatena R. Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation. Adv Exp Med Biol
2012;942:287-308.
58. Ho PC, Liu PS. Metabolic communication in tumors: a new layer of immunoregulation for immune evasion. J Immunother Cancer
2016;4:4.
59. Ludvik AE, Pusec CM, Priyadarshini M, Angueira AR, Guo C, et al. HKDC1 Is a Novel Hexokinase Involved in Whole-Body Glucose Use.
Endocrinology 2016;157:3452-61.
60. Herman MA, Peroni OD, Villoria J, Schon MR, Abumrad NA, et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose
metabolism. Nature 2012;484:333-8.
61. Hitosugi T, Chen J. Post-translational modifications and the Warburg effect. Oncogene 2014;33:4279-85.
62. Clark O, Yen K, Mellinghoff IK. Molecular Pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer Res 2016;22:1837-42.
63. Santarpia L, Bottai G, Kelly CM, Gyorffy B, Szekely B, et al. Deciphering and targeting oncogenic mutations and pathways in breast can-
cer. Oncologist 2016;21:1063-78.
64. Tian GY, Zang SF, Wang L, Luo Y, Shi JP, et al. Isocitrate dehydrogenase 2 suppresses the invasion of hepatocellular carcinoma cells via
matrix metalloproteinase 9. Cell Physiol Biochem 2015;37:2405-14.
65. Yi WR, Li ZH, Qi BW, Ernest ME, Hu X, et al. Downregulation of IDH2 exacerbates the malignant progression of osteosarcoma cells via
increased NF-kappaB and MMP-9 activation. Oncol Rep 2016;35:2277-85.